product name Ethynodiol diacetate
Description: Ethynodiol diacetate is one of the first synthetic progestogens used in contraceptive pills. Nordihydroguaiaretic acid (NDGA) (< 1.5 μM) decreases the percentage of sister chronnatid exchanges (SCEs) in human lymphocyte culture treated with ethynodiol diacetate (150 μg/mL). Since the NDGA treatment, in the presence of S9 mix, reduce the genotoxic damage by ethynodiol diacetate, the reduction may be due to the inhibition of cytochrome P450s which prevents the metabolic activation of ethynodiol diacetate or NDGA may act as a free radical scavenger.
References: J Environ Biol. 2007 Apr;28(2):279-82; Endocr Regul. 1998 Sep;32(3):125-131.
Formula
CAS No.
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO:
Water: <1 mg/mL
Ethanol:
Solubility (In vivo)
Synonyms
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19418747
| In Vitro |
In vitro activity: Nordihydroguaiaretic acid (NDGA) (< 1.5 μM) decreases the percentage of sister chronnatid exchanges (SCEs) in human lymphocyte culture treated with ethynodiol diacetate (150 μg/mL). Since the NDGA treatment, in the presence of S9 mix, reduce the genotoxic damage by ethynodiol diacetate, the reduction may be due to the inhibition of cytochrome P450s which prevents the metabolic activation of ethynodiol diacetate or NDGA may act as a free radical scavenger. Ethynodiol diacetate (150 μg/mL) increases sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) frequencies and inhibits lymphocyte proliferation in the presence of S9 mix in human lymphocyte. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Ethynodiol diacetate (6 mg/kg b.w. daily) significantly increases the amounts of excreted 3alpha-hydroxy-5alpha-pregnan-20-one and A-homo-3-oxa-5alpha-pregnane-4,20-dione in urine in female rats. Significant increase in the weights of pituitary, liver and kidneys are noted in rats treated with ethynodiol diacetate (6 mg/kg b.w. daily). Norgestrel (75 μg/day) and ethynodiol diacetate (150 μg/day), co-administered with ethinyl estradiol (7.5 μg/day), lowers the plasma concentrations of HDL cholesterol in cynomolgus monkeys. |
| Animal model | |
| Formulation & Dosage | |
| References | J Environ Biol. 2007 Apr;28(2):279-82; Endocr Regul. 1998 Sep;32(3):125-131. |
